Multi-omic analysis in injured humans: Patterns align with outcomes and treatment responses.
PAMPer trial
endotype
host response
metabolomics
multi-omics
outcome
proteomics
systemic storm
thawed plasma
trauma
Journal
Cell reports. Medicine
ISSN: 2666-3791
Titre abrégé: Cell Rep Med
Pays: United States
ID NLM: 101766894
Informations de publication
Date de publication:
21 12 2021
21 12 2021
Historique:
received:
22
02
2021
revised:
18
08
2021
accepted:
23
11
2021
entrez:
14
1
2022
pubmed:
15
1
2022
medline:
4
3
2022
Statut:
epublish
Résumé
Trauma is a leading cause of death and morbidity worldwide. Here, we present the analysis of a longitudinal multi-omic dataset comprising clinical, cytokine, endotheliopathy biomarker, lipidome, metabolome, and proteome data from severely injured humans. A "systemic storm" pattern with release of 1,061 markers, together with a pattern suggestive of the "massive consumption" of 892 constitutive circulating markers, is identified in the acute phase post-trauma. Data integration reveals two human injury response endotypes, which align with clinical trajectory. Prehospital thawed plasma rescues only endotype 2 patients with traumatic brain injury (30-day mortality: 30.3 versus 75.0%; p = 0.0015). Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) was identified as the most predictive circulating biomarker to identify endotype 2-traumatic brain injury (TBI) patients. These response patterns refine the paradigm for human injury, while the datasets provide a resource for the study of critical illness, trauma, and human stress responses.
Identifiants
pubmed: 35028617
doi: 10.1016/j.xcrm.2021.100478
pii: S2666-3791(21)00350-5
pmc: PMC8715070
doi:
Substances chimiques
Proteome
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
100478Subventions
Organisme : NIGMS NIH HHS
ID : T32 GM008516
Pays : United States
Organisme : NHLBI NIH HHS
ID : UM1 HL120877
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM119526
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM127027
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL141080
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL135823
Pays : United States
Commentaires et corrections
Type : CommentIn
Déclaration de conflit d'intérêts
Y.V. is co-founder and a stakeholder in Immunetrics. H.A.P. is a consultant for Avita Medical and Spectral MD. M.D.N. holds an equity stake in Haima Therapeutics. He has received research support and/or honoraria from Haemonetics, Instrumentation Laboratories, and Janssen Pharmaceuticals. T.R.B. is a stakeholder in Immunetrics. Other authors declare no conflict of interests.
Références
Antioxid Redox Signal. 2015 Dec 10;23(17):1370-87
pubmed: 26560096
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
N Engl J Med. 2018 Jan 25;378(4):370-379
pubmed: 29365303
Dtsch Arztebl Int. 2014 Jun 20;111(25):437-45; quiz 446
pubmed: 25008311
Blood. 2019 Feb 28;133(9):906-918
pubmed: 30642917
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Crit Care. 2017 Feb 9;21(1):25
pubmed: 28179016
Lancet. 2016 Oct 1;388(10052):1417-1426
pubmed: 27707498
Anesthesiology. 2012 Dec;117(6):1276-88
pubmed: 23168430
Hepatology. 2019 Aug;70(2):725-736
pubmed: 30653682
Cell. 2020 Jul 9;182(1):59-72.e15
pubmed: 32492406
Thromb Res. 2016 May;141 Suppl 2:S50-4
pubmed: 27207425
Nat Med. 2018 Oct;24(10):1590-1598
pubmed: 30177821
Nat Med. 2020 Mar;26(3):333-340
pubmed: 32066974
N Engl J Med. 2018 Jul 26;379(4):315-326
pubmed: 30044935
J Trauma Acute Care Surg. 2015 Sep;79(3):490-2
pubmed: 26307885
Semin Immunol. 2013 Feb;25(1):73-8
pubmed: 23768898
Intensive Care Med. 2004 Jun;30(6):1051-7
pubmed: 15069597
Blood. 2018 May 3;131(18):2001-2006
pubmed: 29507078
Ann Surg. 2016 Jan;263(1):191-8
pubmed: 25371118
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
Br J Haematol. 2018 Mar;180(6):782-798
pubmed: 29265338
Proc Natl Acad Sci U S A. 2012 Dec 4;109(49):19971-6
pubmed: 23139410
Nat Med. 2020 Jan;26(1):29-38
pubmed: 31932803
Blood. 2016 Aug 25;128(8):1043-9
pubmed: 27381903
Mol Med. 2006 Apr-Jun;12(4-6):105-14
pubmed: 16953558
JCI Insight. 2021 Jan 25;6(2):
pubmed: 33320841
Crit Care. 2009;13(6):R174
pubmed: 19887013
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
J Am Coll Surg. 2014 Sep;219(3):335-45
pubmed: 25067800
Sci Rep. 2017 Oct 27;7(1):14248
pubmed: 29079756
Cell Death Dis. 2014 Aug 14;5:e1370
pubmed: 25118930
Cell. 2020 Sep 3;182(5):1311-1327.e14
pubmed: 32888495
Am J Respir Crit Care Med. 2013 Jan 15;187(2):160-9
pubmed: 23220920
Crit Care Med. 2015 Jul;43(7):1395-404
pubmed: 25803650
Lancet Neurol. 2018 Sep;17(9):782-789
pubmed: 30054151
Crit Care Med. 2013 May;41(5):1175-85
pubmed: 23388514
JCI Insight. 2020 Apr 23;5(8):
pubmed: 32229722
JAMA Netw Open. 2020 Oct 1;3(10):e2016869
pubmed: 33057642
Ann Surg. 2011 Aug;254(2):194-200
pubmed: 21772125
Nature. 2018 Dec;564(7735):268-272
pubmed: 30479382
Nat Immunol. 2018 Apr;19(4):327-341
pubmed: 29507356
J Exp Med. 2011 Dec 19;208(13):2581-90
pubmed: 22110166
Nat Commun. 2022 Nov 10;13(1):6789
pubmed: 36357394
J Am Coll Surg. 2021 Mar;232(3):276-287.e1
pubmed: 33453380
J Trauma Acute Care Surg. 2015 Apr;78(4):671-86
pubmed: 25742245
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
Lancet. 2020 Oct 17;396(10258):1204-1222
pubmed: 33069326
Intensive Care Med. 2016 Apr;42(4):551-561
pubmed: 26912315
Nature. 2010 Mar 4;464(7285):104-7
pubmed: 20203610
J Thromb Haemost. 2020 Mar;18(3):740-747
pubmed: 32112533